News for Healthier Living
Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months
Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease
August 29, 2026
August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026August 21 2026August 20 2026August 19 2026August 18 2026August 17 2026August 16 2026
|
|
|
|
|